Biogen Idec Initiates Randomized, Registrational Trial of Lumiliximab for Chronic Lymphocytic Leukemia
Novel anti-CD23 antibody granted Fast Track and Orphan Drug designations
09-Feb-2007 -
Biogen Idec announced that it has initiated a randomized, controlled, registration trial of an investigational anti-CD23 monoclonal antibody, lumiliximab, for patients with chronic lymphocytic leukemia (CLL). The trial will compare treatment with lumiliximab in combination with fludaribine, ...
Biogen Idec
chronic lymphocytic leukemia
cyclophosphamide
+2